Identification

Summary

Technetium Tc-99m pertechnetate is a radiocontrast agent used for the identification of various organs, including but not limited to the brain, thyroid, placenta, and bladder.

Generic Name
Technetium Tc-99m pertechnetate
DrugBank Accession Number
DB09314
Background

Technetium Tc-99m pertechnetate is a radiopharmaceutical diagnostic agent composed of an oxoanion with the chemical formula TcO4-. Pertechnetate has a wide variety of uses within nuclear medicine as it distributes within the body to a similar extent as iodine. It also concentrates in the thyroid gland, salivary glands, gastric mucosa, and choroid plexus. However, in contrast to the iodide ion, the pertechnetate ion is released unchanged from the thyroid gland. Currently marketed as the product Drytec, technetium-99m pertechnetate is indicated for imaging of the following tissues: thyroid, salivary gland, urinary bladder (for detection of vesico-ureteral reflux), and the nasolacrimal drainage system.

Technetium-99m's short half life (6 hours) makes storage impossible, therefore it is supplied as its parent nuclide molybdenum-99, which spontaneously decays to technetium-99 through beta decay. This is normally supplied in a hospital setting through the use of a technetium-99m generator, whereby technetium exits the generator in the form of the pertechnetate ion, TcO4−, which can be extracted and promptly used for clinical diagnostics. Following intravenous injection, single photon emission computed tomography (SPECT) is performed to detect the gamma ray emmitted by the decay of Technetium-99m to Technetium-99.

Type
Small Molecule
Groups
Approved, Investigational
Structure
Thumb
Weight
Average: 169.968
Monoisotopic: 169.95002301
Chemical Formula
H8O4Tc
Synonyms
  • (99Tc)pertechnetate
  • CPERT
  • GPERT
  • Pertechnetate-99Tc
  • Technetium (99mTc) Pertechnetate
  • Technetium Tc 99m Pertechnetate

Pharmacology

Indication

Sodium Pertechnetate Tc99m Injection is indicated for use in adults for imaging in the following tissues: thyroid, salivary gland, urinary bladder (for detection of vesico-ureteral reflux), and nasolacrimal drainage system (dacryoscintigraphy). It is indicated for use in children for imaging the following tissues: thyroid and urinary bladder.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

The pertechnetate ion distributes in the body similarly to the iodide ion, but is not organified when trapped in the thyroid gland. It also concentrates in the thyroid gland, salivary glands, gastric mucosa, and choroid plexus. However, in contrast to the iodide ion, the pertechnetate ion is released unchanged from the thyroid gland.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
No interactions found.

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Technetium Tc-99m sodium pertechnetateA0730CX80123288-60-0MKADDTFVKFMZGF-UHFFFAOYSA-N
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Drytec (Technetium Tc99m Generator)Generator405 mCi/1mLIntravascularMedi-Physics Inc.2014-04-012019-01-10US flag
Drytec (Technetium Tc99m Generator)Generator1351 mCi/1mLIntravascularMedi-Physics Inc.2014-04-012019-01-10US flag
Drytec (Technetium Tc99m Generator)Generator108 mCi/1mLIntravascularMedi-Physics Inc.2014-04-012019-01-10US flag
Drytec (Technetium Tc99m Generator)Generator243 mCi/1mLIntravascularMedi-Physics Inc.2014-04-012019-01-10US flag
Drytec (Technetium Tc99m Generator)Generator676 mCi/1mLIntravascularMedi-Physics Inc.2014-04-012019-01-10US flag
Drytec (Technetium Tc99m Generator)Generator2027 mCi/1mLIntravascularMedi-Physics Inc.2014-04-012019-01-10US flag
Drytec (Technetium Tc99m Generator)Generator162 mCi/1mLIntravascularMedi-Physics Inc.2014-04-012019-01-10US flag
Drytec (Technetium Tc99m Generator)Generator338 mCi/1mLIntravascularMedi-Physics Inc.2014-04-012019-01-10US flag
Drytec (Technetium Tc99m Generator)Generator1081 mCi/1mLIntravascularMedi-Physics Inc.2014-04-012019-01-10US flag
Drytec (Technetium Tc99m Generator)Generator68 mCi/1mLIntravascularMedi-Physics Inc.2014-04-012019-01-10US flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
POLGENTEC 2-120 GBQ GENERADOR DE RADIONUCLEIDOSTechnetium Tc-99m sodium pertechnetate (120 GBq) + Aluminum oxide (2 g) + Sodium molybdate (0 GBq)SolutionIntravenousISOMEDIX TECHNOLOGY S.A.S.2013-09-19Not applicableColombia flag
TECHNELITE® GENERADOR DE TECNECIO TC 99MTechnetium Tc-99m sodium pertechnetate (0 GBq) + Sodium molybdate (740 GBq)SolutionIntravenousCOMERCIALIZADORA DE MATERIAL CIENTIFICO E INDUSTRIAL SAS - COMCI SAS2006-11-10Not applicableColombia flag
ULTRA TECHNEKOW FM2.15 - 43.00 GBQ GENERADOR DE RADIONÚCLIDO.Technetium Tc-99m sodium pertechnetate (38.1 GBq) + Sodium chloride (9 mg) + Sodium molybdate (43 GBq) + Water (1 mL)SolutionIntraocular; IntravenousCurium Netherlands B.V.2019-03-04Not applicableColombia flag

Categories

ATC Codes
V09FX01 — Technetium (99mtc) pertechnetate
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
PPP8783IQ1
CAS number
23288-61-1
InChI Key
ZTFPRNKAHXDALS-RCUQKECRSA-N
InChI
InChI=1S/4H2O.Tc/h4*1H2;/q;;;;-1/i;;;;1+1
IUPAC Name
tetrahydrate (98Tc)technetiumuide
SMILES
O.O.O.O.[98Tc-]

References

General References
  1. Ryo UY, Vaidya PV, Schneider AB, Bekerman C, Pinsky SM: Thyroid imaging agents: a comparison of I-123 and Tc-99m pertechnetate. Radiology. 1983 Sep;148(3):819-22. [Article]
KEGG Drug
D08761
PubChem Compound
131709156
PubChem Substance
310265199
RxNav
1489762
ChEMBL
CHEMBL2109884
RxList
RxList Drug Page
Wikipedia
Pertechnetate

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedDiagnosticNeoplasms, Thyroid1
1RecruitingTreatmentMetastatic Endometrial carcinoma / Recurrent Endometrial Adenocarcinoma / Recurrent Endometrial Carcinoma / Recurrent Endometrial Clear Cell Adenocarcinoma / Recurrent Endometrial Endometrioid Adenocarcinoma / Recurrent Endometrial Mixed Cell Adenocarcinoma / Recurrent Endometrial Serous Adenocarcinoma / Recurrent Endometrial Undifferentiated Carcinoma / Recurrent Uterine Corpus Carcinosarcoma / Stage IV Uterine Corpus Cancer AJCC v7 / Stage IVA Uterine Corpus Cancer AJCC v7 / Stage IVB Uterine Corpus Cancer AJCC v71

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
GeneratorIntravascular108 mCi/1mL
GeneratorIntravascular1081 mCi/1mL
GeneratorIntravascular135 mCi/1mL
GeneratorIntravascular1351 mCi/1mL
GeneratorIntravascular162 mCi/1mL
GeneratorIntravascular1622 mCi/1mL
GeneratorIntravascular2027 mCi/1mL
GeneratorIntravascular203 mCi/1mL
GeneratorIntravascular230 mCi/1mL
GeneratorIntravascular243 mCi/1mL
GeneratorIntravascular270 mCi/1mL
GeneratorIntravascular2703 mCi/1mL
GeneratorIntravascular338 mCi/1mL
GeneratorIntravascular405 mCi/1mL
GeneratorIntravascular541 mCi/1mL
GeneratorIntravascular676 mCi/1mL
GeneratorIntravascular68 mCi/1mL
GeneratorIntravascular811 mCi/1mL
SolutionIntravenous
SolutionIntravenous
InjectionIntravenous; Intravesical; Ophthalmic12 Ci/12Ci
InjectionIntravenous; Intravesical; Ophthalmic15 Ci/15Ci
InjectionIntravenous; Intravesical; Ophthalmic19 Ci/19Ci
InjectionIntravenous; Intravesical; Ophthalmic6 Ci/6Ci
InjectionIntravenous; Intravesical; Ophthalmic7.5 Ci/7.5Ci
SolutionIntravenous0.4 gbq
Injection, solutionIntravenous250 mCi/1mL
GeneratorIntravenous; Ophthalmic
SolutionIntraocular; Intravenous
Injection, solutionIntravenous1 Ci/1
Injection, solutionIntravenous1.5 Ci/1
Injection, solutionIntravenous11 Ci/1
Injection, solutionIntravenous14 Ci/1
Injection, solutionIntravenous16 Ci/1
Injection, solutionIntravenous19 Ci/1
Injection, solutionIntravenous2 Ci/1
Injection, solutionIntravenous2.5 Ci/1
Injection, solutionIntravenous3 Ci/1
Injection, solutionIntravenous3.5 Ci/1
Injection, solutionIntravenous5 Ci/1
Injection, solutionIntravenous6 Ci/1
Injection, solutionIntravenous7.5 Ci/1
SolutionIntravenous3.6 mg/L
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility137.0 mg/mLALOGPS
logP-1.4ALOGPS
logP-0.65ChemAxon
logS0.61ALOGPS
pKa (Strongest Acidic)15.7ChemAxon
pKa (Strongest Basic)-1.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area25.3 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity3.7 m3·mol-1ChemAxon
Polarizability1.51 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at November 16, 2015 22:49 / Updated at October 09, 2021 02:48